"Genentech combines the best of 2 worlds: Academia and Industry. The collegiality and the diversity are paramount to Genentech's success. I feel lucky and privileged to work with amazing colleagues in such a supportive and innovative environment."
I am a Senior Scientist/Toxicologist in the Safety Assessment Department. I serve as the nonclinical lead or project toxicologist for several ocular projects in research or early development with a focus on long acting delivery strategies.
Prior to joining Genentech in late 2013, I contributed to the nonclinical development of therapies for rare pediatric skeletal diseases, from early stage research to market application.
My PhD and postdoctoral works focused on bone biology from osteoclast biology to mesenchymal stem cell differentiation.
Mol Pharm. 2016 Sep 6;13(9):2891-6
Since joining Genentech in 2013, I have been involved in the nonclinical development of new therapies for the treatment of Age-Related Macular Degeneration (AMD) as well as new strategies to reduce the frequency of dosing in the back of the eye.
I closely collaborate with colleagues across the company (including Research, Development Science and Technical Development) and external partners to investigate the cause for toxicity, inform the design of the next generation of drug carrier and develop and implement a path forward to bring these new molecules or technologies to the patients.